Mohit Kaushal

Mohit Kaushal’s career has spanned investing, technology, clinical medicine/academia, and public policy. Dr. Kaushal is a seasoned investor with extensive experience in being both a public and private company board member. He is an investor/ independent board member to numerous transformational companies including Oak Street Health (NYSE:OSH) (acquired by CVS Health, NYSE:CVS), Humedica (acquired by Optum Health), Rxante (acquired by Millennium), Change Healthcare (acquired by Emdeon), Universal American (NYSE:UAM) (acquired by WellCare, NYSE:WCG), CitiusTech (acquired by Baring), Gravie, Wellframe (acquired by HealthEdge), Elation Health, The Oncology Institute (NASDAQ:TOI).

In addition, Dr. Kaushal is an Adjunct Professor at Stanford University within the newly created Biomedical Data Science Department. He continues to be active within public policy and is a Scholar in Residence at the Duke Margolis Center for Health Policy.

Dr. Kaushal is an ER physician, holds an MBA from Stanford and an MD with distinction from Imperial College of Science, Technology and Medicine, London.